NASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Free bmea Stock Alerts $5.64 -0.17 (-2.93%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$5.57▼$6.1050-Day Range$4.14▼$13.2852-Week Range$3.61▼$38.84Volume2.27 million shsAverage Volume1.95 million shsMarket Capitalization$202.70 millionP/E RatioN/ADividend YieldN/APrice Target$28.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Biomea Fusion alerts: Email Address Biomea Fusion MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside400.9% Upside$28.25 Price TargetShort InterestHealthy42.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.10Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.09) to ($3.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.21 out of 5 starsMedical Sector349th out of 915 stocksPharmaceutical Preparations Industry161st out of 430 stocks 4.3 Analyst's Opinion Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageBiomea Fusion has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biomea Fusion's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted42.88% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 9.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BMEA. Previous Next 2.2 News and Social Media Coverage News SentimentBiomea Fusion has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Biomea Fusion this week, compared to 2 articles on an average week.Search Interest14 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders27.57% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($4.09) to ($3.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Biomea Fusion Stock (NASDAQ:BMEA)Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Read More BMEA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMEA Stock News HeadlinesJune 14 at 4:00 PM | businesswire.comBiomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsJune 13 at 6:14 PM | businesswire.comRosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEAJune 13 at 2:22 PM | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEAJune 12 at 3:28 AM | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Lowered to "Hold" at Truist FinancialJune 11, 2024 | benzinga.comThis Cleveland-Cliffs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayJune 9, 2024 | americanbankingnews.comPiper Sandler Trims Biomea Fusion (NASDAQ:BMEA) Target Price to $10.00June 9, 2024 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) PT Lowered to $21.00 at ScotiabankJune 8, 2024 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Price Target Cut to $15.00June 8, 2024 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Price Target Lowered to $45.00 at CitigroupJune 7, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biomea Fusion, Inc. - BMEAJune 7, 2024 | investorplace.comWhy Is Biomea Fusion (BMEA) Stock Down 63% Today?June 7, 2024 | americanbankingnews.comBiomea Fusion (NASDAQ:BMEA) Downgraded by BarclaysJune 7, 2024 | investorplace.comRide the Gamma Wave: 3 Stocks on the Verge of a Short SqueezeJune 6, 2024 | globenewswire.comBiomea Fusion Announces BMF-219 in Diabetes Placed on Clinical HoldMay 30, 2024 | globenewswire.comBiomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 DiabetesMay 28, 2024 | finance.yahoo.comIs Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?May 3, 2024 | investorplace.comBMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comBiomea Fusion Reports First Quarter 2024 Financial Results and Corporate HighlightsMay 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | msn.com3 Best Stocks to Buy Now, 4/4/2024, According to Top AnalystsApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Biomea Fusion on Promising BMF-219 Clinical Results and Strong Financial PositionApril 1, 2024 | globenewswire.comBiomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | investorplace.comBMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023April 1, 2024 | benzinga.comRecap: Biomea Fusion Q4 EarningsApril 1, 2024 | globenewswire.comBiomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219See More Headlines Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today6/15/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Target$28.25 High Stock Price Target$60.00 Low Stock Price Target$5.00 Potential Upside/Downside+400.9%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-117,250,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-69.88% Return on Assets-60.44% Debt Debt-to-Equity RatioN/A Current Ratio5.84 Quick Ratio5.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book1.19Miscellaneous Outstanding Shares35,940,000Free Float26,035,000Market Cap$202.70 million OptionableOptionable Beta-0.35 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Thomas Andrew Butler (Age 43)Co-Founder, Chairman & CEO Comp: $950.41kMr. Ramses M. Erdtmann (Age 61)Co-Founder, President, COO & Director Mr. Franco Valle (Age 43)CFO & Principal Accounting Officer Comp: $673.66kDr. Juan Pablo Frias M.D.Chief Medical OfficerMr. Heow Tan (Age 65)Chief Technology & Quality Officer Ms. Naomi CretcherChief People OfficerDr. Thorsten Kirschberg Ph.D. (Age 54)Executive Vice President of Chemistry Dr. Stephan Morris M.D.Chief Development OfficerMr. Ravi UpasaniExecutive Vice President of Intellectual PropertyCaroline Perez- DupontSenior Vice President of ContractsMore ExecutivesKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKChiasmaNASDAQ:CHMAEpizymeNASDAQ:EPZMArriVent BioPharmaNASDAQ:AVBPGH ResearchNASDAQ:GHRSView All CompetitorsInstitutional OwnershipIkarian Capital LLCSold 397,000 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCBought 100 shares on 5/17/2024Ownership: 0.000%Janus Henderson Group PLCSold 432,967 shares on 5/16/2024Ownership: 3.576%Bayesian Capital Management LPBought 27,041 shares on 5/16/2024Ownership: 0.075%California State Teachers Retirement SystemSold 1,042 shares on 5/16/2024Ownership: 0.064%View All Institutional Transactions BMEA Stock Analysis - Frequently Asked Questions Should I buy or sell Biomea Fusion stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks. What is Biomea Fusion's stock price target for 2024? 9 Wall Street research analysts have issued 1 year price objectives for Biomea Fusion's stock. Their BMEA share price targets range from $5.00 to $60.00. On average, they expect the company's share price to reach $28.25 in the next year. This suggests a possible upside of 400.9% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts. How have BMEA shares performed in 2024? Biomea Fusion's stock was trading at $14.52 at the beginning of 2024. Since then, BMEA stock has decreased by 61.2% and is now trading at $5.64. View the best growth stocks for 2024 here. Are investors shorting Biomea Fusion? Biomea Fusion saw a decrease in short interest during the month of May. As of May 31st, there was short interest totaling 11,930,000 shares, a decrease of 9.2% from the May 15th total of 13,140,000 shares. Based on an average daily volume of 1,220,000 shares, the short-interest ratio is presently 9.8 days. Currently, 42.9% of the shares of the company are sold short. View Biomea Fusion's Short Interest. When is Biomea Fusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our BMEA earnings forecast. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its earnings results on Thursday, May, 2nd. The company reported ($1.09) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.07. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Biomea Fusion's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.80%), Janus Henderson Group PLC (3.58%), Price T Rowe Associates Inc. MD (0.49%), Ikarian Capital LLC (0.00%), Simplex Trading LLC (0.00%) and Griffin Asset Management Inc. (0.11%). Insiders that own company stock include A2a Pharmaceuticals, Inc, Bihua Chen, Franco Valle, Michael JM Hitchcock and Rainer M Erdtmann. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMEA) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.